RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis
Key claim: A randomized, double-blind, double-dummy active-controlled trial is testing whether denosumab (RANK-ligand inhibition) is efficacious for treating sarcopenia in people with underlying osteoporosis.
Abstract
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
Why this matters
Sarcopenia and osteoporosis frequently co-occur, and RANKL signaling is one of the few molecular pathways plausibly shared by the bone-muscle unit — making an approved anti-RANKL antibody a natural repurposing candidate for muscle aging. This trial is one of the first active-controlled double-blind RCTs to test that hypothesis in humans, but with no outcomes reported it belongs on the protocol shelf, not the evidence shelf, and does not displace resistance training as the human-evidenced sarcopenia lever.